This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

Hep C Drug Updates: Vertex and Anadys

BOSTON (TheStreet) -- Vertex Pharmaceuticals (VRTX) shares are rebounding Thursday on speculation that prescription growth of its hepatitis C drug Incivek may not be flattening as much as previously feared.

Anadys Pharmaceuticals (ANDS) also released Thursday new mid-stage data on its experimental Hep C drug setrobuvir, which the company hopes will re-ignite partnership talks. More on Anadys in a moment, first let's tackle Vertex and the case of the missing Incivek mail-order scripts…

Wednesday night, IMS Health issued a bulletin to subscribers explaining that a "significant portion" of mail-order prescription data for Incivek was not reported correctly for the last two weeks of September. IMS used historical mail-order data as a replacement, but the research service conceded that the Incivek prescription numbers reported as a result may not have been entirely accurate.

And those IMS numbers have shown Vertex's Incivek prescription growth flat for September, which had investors worried about what was happening following the drug's rocket-like launch this spring. If Incivek prescriptions remain on this flat trend-line, meeting sales expectations for the rest of 2011, and more importantly 2012, could be difficult.

This explains why Vertex's stock price has been so weak lately.

Unless, of course, IMS' prescription data for Incivek, which much of the Street reads on a weekly basis, is totally screwed up and has been under-counting what's really going on with Incivek.

IMS has fixed the problem of the missing mail-order data and will announce a detailed update on Monday, Oct. 17. It's possible that IMS is actually over-counting Incivek prescriptions but on Thursday at least, investors were hopeful and betting that Incivek's numbers are actually better than what's been previously reported.

Hence, Vertex shares are up $2.65, or 6.5%, to $42.91 Thursday.

Vertex, itself, will release actual third-quarter Incivek sales when the company reports earnings on Oct. 27.

Moving to Anadys: The new setrobuvir results from a phase IIb study announced Thursday look okay from an efficacy and safety perspective but the data aren't going to prompt investors to scream "wow" like they are when Pharmasset says anything about its experimental Hep C drugs.

Stock quotes in this article: VRTX, ANDS, VRUS 

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 +2.54 0.14%
NASDAQ 4,095.5160 +9.2910 0.23%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs